Company Overview and News

FNSR / Finisar Corporation / VANGUARD GROUP INC - null (Passive Investment)

2018-10-10 - 1
finisarcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FNSR / Finisar Corporation / VANGUARD GROUP INC - null (Passive Investment)

finisarcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Why Is Finisar (FNSR) Down 3.1% Since Last Earnings Report?

2018-10-06 zacks - 1
A month has gone by since the last earnings report for Finisar (FNSR - Free Report) . Shares have lost about 3.1% in that time frame, underperforming the S&P 500.

Finisar may have benefited from Applied Opto's stumbles, says Piper Jaffray

2018-09-28 marketwatch - 1
Shares of Applied Optoelectronics Inc. AAOI, -14.03% are down 12.7% in Friday morning trading after the company cut its revenue forecast owing to a problem with a small portion of 25G lasers related to a specific customer. Piper Jaffray analyst Troy Jensen thinks the rest of the industry looks fine and argued that Finisar Corp. FNSR, +0.34% might have benefited by the quality issues at Applied Opto.

Finisar to Gain From Enhanced Product Offerings, Risks Stay

2018-09-24 zacks - 2
On Sep 24, we issued an updated research report on Finisar Corporation (FNSR - Free Report) , a components and subsystems provider. Finisar is expanding its broad product line of optical subsystems through dedicated R&D activities to meet the evolving customer needs, which augurs well for its long-term growth. However, the company remains mired in various operating risks, particularly in China that impair its growth potential to some extent.

Finisar Introduces 400G QSFP-DD DR4 Transceiver for Data Center Applications and the Industry’s First 64 Gbaud Coherent Integrated Assembly at ECOC 2018

2018-09-24 globenewswire
SUNNYVALE, Calif. and ROME, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Finisar (NASDAQ: FNSR) today introduced several new product and technology demonstrations taking place this week at ECOC, the European Conference on Optical Communications in Rome, Italy. Several 200G and 400G transceivers will be demonstrated, including 400G QSFP-DD DR4, 400G QSFP-DD eLR8 (extended-reach), 200G QSFP56 FR4 and 200G QSFP56 eFR4.

Finisar Shipping Transceivers with new Flextune™ Self-Tuning Capability

2018-09-24 globenewswire
SUNNYVALE, Calif. and ROME, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Finisar (NASDAQ: FNSR) today announced the sample availability of its new Flextune™ self-tuning feature for tunable DWDM transceiver modules. See a demonstration of this capability in Finisar's booth #400 at ECOC 2018 from September 24 through 26.

Finisar Innovators to Speak at ECOC 2018 in Rome

2018-09-17 globenewswire
What: Finisar, a global technology leader in optical communications, today announced a line-up of speakers at the ECOC Conference and Exhibition. This group of industry experts will contribute to discussions on the challenges and opportunities within the optics industry. Where: Fiera Roma Exhibition and Trade Center, ROME When: September 23- 27, 2018

Telecom Stock Roundup: Verizon 5G Internet Service, Ericsson-T-Mobile 5G Deal & More

2018-09-13 zacks - 1
In the past five trading days, the uptrend in telecom stocks continued driven by healthy job growth data exhibiting signs of a strengthening economy. The stocks were also fueled by optimism from a U.S. proposal to initiate talks with China in the near future to iron out the trade-related differences between the two countries. Per the U.S. Labor Department report, about 201,000 new jobs were created in August, marking the 95th straight month of employment gains in the country.

Finisar, Ciena stocks fall on Morgan Stanley downgrades

2018-09-13 marketwatch - 1
Shares of Finisar Corp. FNSR, -0.20% and Ciena Corp. CIEN, +1.09% are down 4.2% and 2.8%, respectively, in premarket trading Thursday after Morgan Stanley analyst Meta Marshall downgraded the stocks to equal-weight from overweight. "Finisar and Ciena have closed the short-term valuation gaps that we believed existed," Marshall wrote. "While we think both stocks could continue to move toward our bull cases, we think those catalysts for further positive moves are in CY19, causing us to move to the sidelines for now.

Applied Optoelectronics: Tariff Narrative Is Overblown And The Stock Is Undervalued

2018-09-13 seekingalpha - 3
A research analyst at B. Riley issued a note for optical component manufacturers citing some concerns.

Apple unveils larger iPhones, health-oriented watches

2018-09-12 channelnewsasia - 1
Apple Inc unveiled larger iPhones and watches based on the design of current models on Wednesday, confirming expectations that the company is making only minor changes to its lineup.

FNSR / Finisar Corporation 8-K (Current Report)

2018-09-10 - 1

SHU Portfolio: Finisar Should Embrace More Outsourcing

2018-09-08 seekingalpha
Finisar produced good Q1 results and the next couple of years look promising for the company.

Apple says US tariffs on China would hit #39;wide range#39; of products

2018-09-08 moneycontrol
A "wide range" of Apple Inc products including the Apple Watch would be affected by proposed US tariffs on Chinese goods, the company told US trade officials but gave no sign of an impact on its iPhone cash cow.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to FNSR / Finisar Corporation on message board site Silicon Investor.

Finisar - FNSR Finisar - FNSR Finisar - FNSR
CUSIP: 31787A507